论文部分内容阅读
1文献来源Wolf J,Seto T,Han J Y,et al.Capmatinib in MET exon 14⁃mutated or MET⁃amplified non⁃small⁃cell lung cancer[J].N Engl J Med,2020,383(10):944-957.2证据水平1a。3背景在非小细胞肺癌(non⁃small cell lung cancer,NSCLC)中,MET 14外显子跳跃突变(跳读)发生率在3%~4%,而MET扩增发生率为1%~6%。Capmatinib